| Primary information |
|---|
| OV_ID | OV_4109 |
| Virus Name | Vaccinia virus |
| Strain | VVstrain GLV-5b451 |
| Virus type | DNA |
| Virus family | Poxviridae |
| Modification in virus genome | Derived from LIVP6.1.1 by inserting glaf-2 gene into J2R locus |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | No |
| Source of cell line | University of colorado, USA |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | Hsd athymic nude mice xenograft for STSA-1 cell line (1 × 10â¶) |
| In-vivo virus concentration | 1 × 10ⷠpfu
|
| In-vivo toxicity | NA |
| In-vivo result | Tumor volume reduced to 200 mm compared to control 2500mm after 49 days |
| Mode of delivery | Intravenous |
| Pathway induction | NA |
| Immunogenic effect | NA |
| Clinical trial | NA |
| PMID | 26205404 |